Healthcare use after screening for lung cancer

Authors

  • Margaret M. Byrne PhD,

    Corresponding author
    1. Department of Epidemiology and Public Health, University of Miami Miller School of Medicine, Miami, Florida
    2. Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida
    • Department of Epidemiology and Public Health and Sylvester Comprehensive Cancer Center, 1120 NW 14th Street, University of Miami, Miami, FL 33136
    Search for more papers by this author
    • Fax: (305) 243-2997

  • Tulay Koru-Sengul PhD,

    1. Department of Epidemiology and Public Health, University of Miami Miller School of Medicine, Miami, Florida
    2. Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida
    Search for more papers by this author
  • Wei Zhao MD, MS,

    1. Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida
    Search for more papers by this author
  • Joel L. Weissfeld PhD,

    1. Department of Epidemiology, University of Pittsburgh, Pittsburgh, Pennsylvania
    Search for more papers by this author
  • Mark S. Roberts MD, MPP

    1. Division of General Internal Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania
    Search for more papers by this author

  • We express our deep gratitude for invaluable research assistance from Cleve Heller and Lisa Schiller. In addition, we thank those at the Department of Internal Medicine, University of Pittsburgh, for providing space and resources throughout this project.

Abstract

BACKGROUND:

To evaluate the benefits of lung cancer screening, all effects of screening need to be considered. The aim of this study was to determine whether screening had an effect on healthcare use, specifically whether use increased for those with a false-positive or indeterminate screening result.

METHODS:

Recruited were 400 individuals participating in a lung cancer screening study at the University of Pittsburgh. Self-reported outpatient healthcare use information was collected for the 6 months before, 0 to 6 months after, and 6 to 12 months after screening. The screening outcomes were negative, indeterminate, and suspicious. Repeated-measures Poisson regression models were used to examine changes in use over time and how changes over time varied among the screening outcome groups.

RESULTS:

Approximately 58% of participants had a negative screening result, 36% had an indeterminate result, and approximately 6% had a suspicious result. The percentage of individuals who had any incidence of each type of outpatient use increased after screening, with the greatest increase noted for those with a suspicious screening result. Adjusted mean use significantly increased for nearly all types of use and for all 3 screening results categories in the 6 months after screening, but mostly declined to prescreening levels in the next 6 months.

CONCLUSIONS:

Outpatient healthcare use was found to increase after screening for all individuals who were screened for lung cancer, regardless of the screening finding. The cost of the lung-related visits alone was substantial. Therefore, if lung cancer screening prevalence is increased, attendant follow-up healthcare costs are also likely to increase. Cancer 2010. © 2010 American Cancer Society.

Ancillary